Eli Lilly (LLY) made up for a first-quarter earnings miss with a raised outlook and positive obesity-trial data for a potential blockbuster drug.
You are here: Home / Eli Lilly’s higher guidance, Mounjaro data set the Club name up for a solid 2023
Market News and Views
Eli Lilly (LLY) made up for a first-quarter earnings miss with a raised outlook and positive obesity-trial data for a potential blockbuster drug.